Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 715 results

Media Release / Aug 11, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Media Release / Jul 31, 2025

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Media Release / Jul 03, 2025

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Media Release / Jun 02, 2025

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Media Release / Jun 01, 2025

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
Media Release / May 15, 2025

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
Media Release / Apr 10, 2025

Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilitiesWith new manufacturing capacity, Novartis will be able to produce 100% of its key…
Media Release / Apr 02, 2025

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Media Release / Mar 28, 2025

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Media Release / Mar 25, 2025

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

‹ Previous page
1
…
3
4
5
6
7
8
9
…
72
› Next page